Welcome to our dedicated page for Assertio Holdings SEC filings (Ticker: ASRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Assertio Holdings, Inc. filings document formal disclosures for a Nasdaq-listed commercial pharmaceutical company, including material-event reports, annual meeting voting results, governance actions, and capital-structure matters. The record includes disclosures on common stock, convertible senior notes, tender-offer communications, and amendments to equity incentive plan provisions.
Assertio's SEC reports also cover material definitive agreements and completed asset-sale disclosures involving branded products such as INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP. These filings describe transaction documents, Regulation FD communications, shareholder approvals, executive-compensation plan matters, and operating subjects tied to the company's pharmaceutical commercialization business.
Assertio Holdings, Inc. (ASRT) notified the Nasdaq Stock Market LLC of the removal of its common stock from listing and/or registration pursuant to Form 25 under Section 12(b) of the Securities Exchange Act of 1934. The notice states the Exchange and the issuer complied with the cited rule sections governing voluntary withdrawal.
Assertio Holdings, Inc. director William McKee reported dispositions of his equity as part of the company’s cash sale to Zydus. A Zydus subsidiary completed a tender offer for all outstanding Assertio common shares at $23.50 per share in cash, followed by a merger that made Assertio a wholly owned subsidiary.
McKee’s 27,936 shares of common stock were cancelled at the merger effective time and converted into the right to receive the $23.50 per-share offer price, less any applicable taxes. Two stock option grants covering 5,415 underlying shares each were also cancelled and converted into cash payments based on the excess of the offer price over their respective exercise prices. Following these transactions, McKee no longer holds Assertio common stock or stock options.
Assertio Holdings, Inc. executive vice president and general counsel Sam Schlessinger reported the cash-out of his equity in connection with the company’s merger with Zydus Worldwide DMCC. A Zydus subsidiary completed a tender offer for all Assertio common shares at $23.50 per share in cash, followed by a merger that made Assertio a wholly owned subsidiary.
Schlessinger disposed of 14,738 shares of common stock pursuant to the tender offer and merger. He also disposed of stock options covering 21,128 shares at an exercise price of $11.77, 12,591 shares at $12.177, and 18,900 shares at $11.8965, as well as 25,748 restricted stock units, all converted into cash or cancelled under the merger agreement mechanics. Following these transactions, his reported holdings in these instruments were reduced to zero.
Assertio Holdings, Inc. director Kirk Sigurd reported disposing of all remaining equity interests in connection with the company’s merger with Zydus. On June 16, 2026, 12,017 shares of common stock were cancelled and converted into the right to receive $23.50 per share in cash under a completed tender offer and merger.
The filing also shows the cancellation and disposition to the issuer of multiple stock option awards over 5,415 shares at $9.2565 per share, 5,415 shares at $15.1500 per share, and 7,913 shares at $17.1000 per share. According to the merger terms, in-the-money options were converted into cash based on the Offer Price, while options with exercise prices at or above $23.50 received no payment. Following these transactions, Sigurd reports zero shares and options remaining.
Assertio Holdings, Inc. director Sravan Kumar Emany reported that all of his equity in the company was cashed out in connection with Assertio’s merger with Zydus Worldwide DMCC. On June 16, 2026, 23,855 shares of common stock were disposed of pursuant to the tender offer at the cash Offer Price of $23.50 per share. In addition, stock options covering 5,415, 5,415 and 1,753 shares of common stock, with exercise prices of $9.2565, $15.1500 and $16.0500 respectively, were cancelled and converted into cash rights under the merger agreement. Following these transactions, the filing shows Emany with zero reported direct holdings of Assertio common stock or related options.